VOR Vor Biopharma Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1817229 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY155.3%
TTM EPS YoY177.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA402.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets127.6%
Debt / equity—
Current ratio13.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.09x
Accruals ratio438.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $34.53M | $25.92M | $17.59M | $19.19M | $14.14M | $261.50M | $26.70M | $25.35M |
| SG&A expense | $23.91M | $21.93M | $17.57M | $16.77M | $13.96M | $12.79M | $6.59M | $5.96M |
| Operating income | -$58.44M | -$47.85M | -$35.16M | -$35.96M | -$28.11M | -$274.28M | -$33.29M | -$31.31M |
| Net income | -$86.73M | -$62.81M | -$219.58M | $1.72B | -$812.68M | -$1.57B | -$32.49M | -$30.71M |
| EBITDA | -$58.41M | -$47.82M | -$35.13M | -$35.94M | -$26.01M | -$272.18M | -$32.47M | -$30.45M |
| EPS (basic) | -1.45 | -1.16 | -5.11 | — | -121.63 | -251.24 | -5.21 | — |
| EPS (diluted) | -1.45 | -1.16 | -5.11 | — | -121.63 | -251.24 | -5.21 | — |
| Weighted avg. shares (diluted) | 59.67M | 54.30M | 43.01M | — | 6.68M | 6.26M | 6.24M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $78.98M | $107.86M | $169.87M | $396.49M | $160.46M | $190.57M | $50.05M | $81.95M |
| Short-term investments | $402.57M | $358.27M | $321.65M | $58.72M | $10.00M | $9.99M | $9.99M | $9.98M |
| Current assets | $490.52M | $475.11M | $500.78M | $458.11M | $172.49M | $204.93M | $64.85M | $96.51M |
| PP&E, net | $623,000 | $648,000 | $565,000 | $533,000 | $271,000 | $0 | $5.99M | $6.58M |
| Total assets | $496.31M | $481.05M | $506.75M | $464.13M | $176.24M | $205.37M | $109.31M | $142.89M |
| Current liabilities | $36.34M | $24.81M | $16.08M | $25.17M | $18.84M | $58.77M | $16.73M | $18.61M |
| Total liabilities | $633.49M | $681.25M | $657.17M | $628.44M | $2.40B | $1.71B | $43.24M | $46.23M |
| Shareholders' equity | -$137.17M | -$200.20M | -$150.42M | -$164.31M | -$2.23B | -$1.51B | $66.07M | $96.66M |
| Shares outstanding | 61.43M | 54.46M | 54.19M | 38.72M | 9.03M | 125.65M | 124.85M | 6.24M |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.75M | -$25.38M | -$38.25M | -$22.80M | -$53.66M | -$35.18M | -$31.07M | -$24.06M |
| Capital expenditure | $25,000 | $120,000 | $48,000 | $314,000 | $244,000 | $152,000 | $231,000 | $72,000 |
| Free cash flow | -$32.77M | -$25.50M | -$38.29M | -$23.11M | -$53.91M | -$35.34M | -$31.30M | -$24.14M |
| Investing cash flow | -$44.78M | -$36.53M | -$263.24M | -$48.97M | -$244,000 | $646,000 | -$230,000 | -$72,000 |
| Financing cash flow | $48.65M | -$106,000 | $74.87M | $307.80M | $21.55M | $175.06M | -$606,000 | $53.29M |
| Depreciation & amortization | $39,000 | $36,000 | $28,000 | $23,000 | $2.10M | $2.10M | $825,000 | $865,000 |
| Stock-based compensation | $9.94M | $9.40M | $8.87M | $7.11M | $8.03M | $1.84M | $1.93M | $1.71M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.